Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.1K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.4K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.4K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

3.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
3.5K
Inhaled Medications01:23

Inhaled Medications

1.1K
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Review of the effects of inhaled steroid therapy on bone.

The International journal of risk & safety in medicine·2013
Same author

Chronic urticaria and angioedema.

Canadian family physician Medecin de famille canadien·2010
Same author

Tetanus Immunization.

Canadian Medical Association journal·2010
Same author

Gamma Globulin and Asthma.

Canadian Medical Association journal·2010
Same author

Betamethasone in the Treatment of Bronchial Asthma.

Canadian Medical Association journal·2010
Same author

Serum osteocalcin and procollagen as markers for the risk of osteoporotic fracture in corticosteroid-treated asthmatic adults.

The Journal of allergy and clinical immunology·1999

Related Experiment Video

Updated: May 6, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 5, 2010

34.4K

Side effects of inhaled corticosteroids

J H Toogood1

  • 1London Health Sciences Centre, University Of Western Ontario, London, Ontario, Canada N6A 4G5.

The Journal of Allergy and Clinical Immunology
|November 18, 1998
PubMed
Summary

Inhaled corticosteroid (ICS) therapy is safer than other asthma drugs, but high doses can cause side effects. Use the lowest effective dose to minimize risks like eye problems and bone density loss.

Area of Science:

  • Pulmonology
  • Pharmacology

Background:

  • Inhaled corticosteroids (ICS) are a cornerstone of asthma management.
  • Comparing ICS risks to other antiasthmatic medications is crucial for patient safety.

Purpose of the Study:

  • To evaluate the safety profile of inhaled corticosteroid (ICS) therapy in asthma patients.
  • To identify potential risks associated with different doses of ICS and other asthma medications.

Main Methods:

  • Review of existing literature and clinical data on ICS and alternative asthma treatments.
  • Analysis of reported side effects, including ocular, growth, and bone metabolism changes.

Main Results:

  • ICS therapy demonstrates a lower risk of morbidity and mortality compared to prednisone, theophylline, and beta2-agonist bronchodilators.

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.9K

Related Experiment Videos

Last Updated: May 6, 2026

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
14:39

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 5, 2010

34.4K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

42.1K
Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis
03:40

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

1.9K
  • Serious side effects from ICS are rare but increase with higher daily doses.
  • Ocular symptoms, reduced growth velocity, and potential bone metabolism changes (especially with high doses) require monitoring.

    • Conclusions:

    • Minimizing ICS risk involves using the lowest effective daily dose for optimal asthma control.
    • Prompt evaluation by an eye specialist is recommended for ocular symptoms during ICS therapy.
    • Further research is needed to understand the long-term impact of ICS on pediatric growth and bone density, and to develop specific guidelines for preventing bone loss.